398 related articles for article (PubMed ID: 22198020)
1. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
[TBL] [Abstract][Full Text] [Related]
2. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
[TBL] [Abstract][Full Text] [Related]
3. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
Naughton C; O'Toole D; Kirik D; Dowd E
Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
Mulcahy P; Walsh S; Paucard A; Rea K; Dowd E
Neuroscience; 2011 May; 181():234-42. PubMed ID: 21277943
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
8. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
[TBL] [Abstract][Full Text] [Related]
9. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Norazit A; Meedeniya AC; Nguyen MN; Mackay-Sim A
Brain Res; 2010 Nov; 1360():119-29. PubMed ID: 20807515
[TBL] [Abstract][Full Text] [Related]
10. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
11. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
12. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
13. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
14. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
15. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.
Nieto M; Gil-Bea FJ; Dalfó E; Cuadrado M; Cabodevilla F; Sánchez B; Catena S; Sesma T; Ribé E; Ferrer I; Ramírez MJ; Gómez-Isla T
Neurobiol Aging; 2006 Jun; 27(6):848-56. PubMed ID: 16006012
[TBL] [Abstract][Full Text] [Related]
16. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
Saravanan KS; Sindhu KM; Mohanakumar KP
Brain Res; 2005 Jul; 1049(2):147-55. PubMed ID: 15936733
[TBL] [Abstract][Full Text] [Related]
17. Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
Betarbet R; Sherer TB; MacKenzie G; Garcia-Osuna M; Panov AV; Greenamyre JT
Nat Neurosci; 2000 Dec; 3(12):1301-6. PubMed ID: 11100151
[TBL] [Abstract][Full Text] [Related]
18. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
Testa CM; Sherer TB; Greenamyre JT
Brain Res Mol Brain Res; 2005 Mar; 134(1):109-18. PubMed ID: 15790535
[TBL] [Abstract][Full Text] [Related]
19. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
Ulusoy A; Decressac M; Kirik D; Björklund A
Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
[TBL] [Abstract][Full Text] [Related]
20. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Sindhu KM; Saravanan KS; Mohanakumar KP
Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
